Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
847 stopped studies mapped to Malignant Bone Marrow Neoplasm and descendants · 88% state a reason
Over the 847 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase 1 | terminated | Aug 13, 2012 | Gilead Sciences | PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD… | Safety / toxicity |
| NCT02229266 | Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy…(HINKL) | Phase 2 | terminated | Sep 1, 2014 | Technische Universität Dresden | low recruitment rate | Enrollment / accrual |
| NCT04217720 | SNS-301 Monotherapy in High Risk MDS and CMML | Phase 2 | withdrawn | Jan 3, 2020 | Sensei Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | Phase 1 / Phase 2 | terminated | Apr 30, 2010 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT04296214 | Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic… | — | withdrawn | Mar 5, 2020 | Grupo Cooperativo de Hemopatías Malignas | Poor recruitment | Enrollment / accrual |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in… | Phase 1 / Phase 2 | terminated | May 12, 2015 | University of Illinois at Chicago | not stated | Not stated |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute… | Phase 1 / Phase 2 | terminated | Dec 7, 2011 | Abramson Cancer Center at Penn Medicine | not stated | Not stated |
| NCT03806192 | Feasibility of Partners in Care Program for Caregivers of Patients With Acute Myeloid… | N/A | terminated | Jan 16, 2019 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and… | Phase 2 | withdrawn | May 20, 2020 | Kiadis Pharma | The sponsor decided to withdraw this study | Sponsor / business decision |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | Phase 4 | terminated | May 26, 2010 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01599429 | Study of the Predictive Marker FLT in Patients Suffering From AML(TEP-FLT-LMA) | — | withdrawn | May 16, 2012 | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | No participants enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Apr 24, 2017 | Sunshine Lake Pharma Co., Ltd. | Company strategy adjustment | Sponsor / business decision |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With… | Phase 1 | terminated | Dec 2, 2017 | AbbVie | Strategic Reasons | Sponsor / business decision |
| NCT02648932 | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With… | Phase 2 | terminated | Jan 7, 2016 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | Phase 1 / Phase 2 | terminated | Apr 13, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03881735 | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With… | Phase 2 | withdrawn | Mar 19, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT04283526 | Study of Select Combinations in Adults With Myelofibrosis | Phase 1 | withdrawn | Feb 25, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT02973711 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | Phase 1 / Phase 2 | withdrawn | Nov 25, 2016 | University of Michigan Rogel Cancer Center | lack of funding | Funding |
| NCT03515707 | Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal… | Phase 2 | withdrawn | May 3, 2018 | Fred Hutchinson Cancer Center | PI recommended closure | Other (stated, no rule matched) |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT00615784 | Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia(UPCC04407) | Phase 2 | terminated | Feb 14, 2008 | Abramson Cancer Center at Penn Medicine | Study terminated. Eisai's Targretin acquired by another pharmaceutical company. | Sponsor / business decision |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | Phase 2 | withdrawn | Nov 14, 2018 | City of Hope Medical Center | RSS recommendation | Other (stated, no rule matched) |
| NCT03709576 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell… | Phase 2 | terminated | Oct 17, 2018 | Milton S. Hershey Medical Center | Funding pulled | Funding |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase… | Phase 1 | terminated | May 25, 2016 | M.D. Anderson Cancer Center | Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to… | Enrollment / accrual |
| NCT04493099 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or… | Phase 1 / Phase 2 | withdrawn | Jul 30, 2020 | M.D. Anderson Cancer Center | The original sponsor was acquired by a new company and has elected to end funding for all… | Investigator |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | Phase 1 / Phase 2 | terminated | Aug 2, 2012 | PrECOG, LLC. | Study stopped per Novartis request due to futility from another study. | Efficacy / futility |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Nov 2, 2016 | M.D. Anderson Cancer Center | PDOL request | Other (stated, no rule matched) |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT04128020 | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation… | Phase 1 | withdrawn | Oct 16, 2019 | Sherif Farag | Funder withdrew funding after not accruing any subjects after 1 year. | Enrollment / accrual |
| NCT03027401 | Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | — | withdrawn | Jan 23, 2017 | National Cancer Institute (NCI) | closed by PI and FDA | Other (stated, no rule matched) |
| NCT00020969 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 2 | terminated | Jan 27, 2003 | CTI BioPharma | not stated | Not stated |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After… | Phase 1 | withdrawn | Jun 1, 2016 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | Phase 3 | terminated | Jan 23, 2013 | CTI BioPharma | not stated | Not stated |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT00506948 | Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute… | Phase 2 | terminated | Jul 25, 2007 | M.D. Anderson Cancer Center | Halted due to high incidence of veno-oclusive disease of the liver. | Other (stated, no rule matched) |
| NCT00726830 | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | N/A | terminated | Aug 1, 2008 | M.D. Anderson Cancer Center | Low Accrual. | Enrollment / accrual |
| NCT01038856 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera(OSI-TAR-766) | Phase 2 | terminated | Dec 24, 2009 | University of Oklahoma | The study was terminated by the sponsor | Other (stated, no rule matched) |
| NCT00914940 | Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts… | Phase 2 | terminated | Jun 5, 2009 | Fred Hutchinson Cancer Center | Did not reach one of the primary endpoints of decreased total acute GVHD | Other (stated, no rule matched) |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT03121599 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms | N/A | terminated | Apr 20, 2017 | Hamad Medical Corporation | Delayed study materials, poor recruitment | Enrollment / accrual |
| NCT02730884 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With… | Phase 2 | terminated | Apr 7, 2016 | M.D. Anderson Cancer Center | Terminated Per PIs request due to low accrual | Enrollment / accrual |
| NCT00004114 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced… | Phase 1 | withdrawn | Feb 16, 2004 | Jonsson Comprehensive Cancer Center | Study never opened | Other (stated, no rule matched) |
| NCT00234000 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 1 | terminated | Oct 6, 2005 | Jonsson Comprehensive Cancer Center | The study was closed due to poor enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 19, 2021source: clinicaltrials